

=> d his.1

(FILE 'HCAPLUS' ENTERED AT 14:50:42 ON 30 APR 2004)
 L25 39 S L16-L18 OR L22-L24

=> d que 125

L1 89 SEA FILE=REGISTRY TGA CTGTGAACGTTTCGAGATGA/SQSN
 L2 206549 SEA FILE=REGISTRY AACGTTTCG|GACGTTTCG/SQSN
 L3 68 SEA FILE=HCAPLUS L1
 L4 5 SEA FILE=HCAPLUS L3 AND PAPILLOMAVIR?
 L5 12815 SEA FILE=HCAPLUS L2
 L6 35 SEA FILE=HCAPLUS L5 AND PAPILLOMAVIR?
 L7 2054727 SEA FILE=REGISTRY [AG][AG]CG[CT][CT]CG/SQSN
 L8 298754 SEA FILE=REGISTRY L7 AND SQL<440
 L9 8470 SEA FILE=HCAPLUS L8
 L10 39 SEA FILE=HCAPLUS L9 AND PAPILLOMAVIR?
 L11 8666 SEA FILE=HCAPLUS L***
 L12 37 SEA FILE=HCAPLUS L11 AND PAPILLOMAVIR?
 L13 8369 SEA FILE=HCAPLUS L***
 L14 38 SEA FILE=HCAPLUS L13 AND PAPILLOMAVIR?
 L15 103 SEA FILE=HCAPLUS L4 OR L6 OR L10 OR L12 OR L14
 L16 1 SEA FILE=HCAPLUS L15 AND ISS
 L17 6 SEA FILE=HCAPLUS L15 AND IMMUNOSTIMULAT?
 L18 2 SEA FILE=HCAPLUS L15 AND CPG
 L19 61 SEA FILE=HCAPLUS L15 AND (TREAT? OR THERAP? OR ADMINIST?)
 L20 68 SEA FILE=HCAPLUS VAN NEST G?/AU OR VANNEST G?/AU
 L21 43 SEA FILE=HCAPLUS EIDEN J?/AU
 L22 2 SEA FILE=HCAPLUS (L20 OR L21) AND L15
 L23 35 SEA FILE=HCAPLUS L19 AND (WART? OR PAPILLOMA# OR CONDYLOMA# OR
 NEOPLAS? OR DYSPLAS?)
 L24 5 SEA FILE=HCAPLUS L19 AND IMMUNOMODULAT?
 L25 39 SEA FILE=HCAPLUS (L16 OR L17 OR L18) OR (L22 OR L23 OR L24)

=> d ibib abs 125 1-39

L25 ANSWER 1 OF 39 HCAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2004:270092 HCAPLUS
 DOCUMENT NUMBER: 140:302327
 TITLE: Human cell lines encoding **immunomodulatory**
 cytokine, chemokine or adjuvant and antigen derived
 from tumor-associated virus for cancer vaccine and
 immunotherapy
 INVENTOR(S): Ambinder, Richard F.; Yang, Yiping; Borrello, Ivan M.;
 Levitsky, Hyam I.
 PATENT ASSIGNEE(S): Johns Hopkins University School of Medicine, USA
 SOURCE: PCT Int. Appl., 218 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004027036	A2	20040401	WO 2003-US29684	20030919
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
 PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
 TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
 CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
 NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
 GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

US 2002-411990P P 20020919

AB A human cell line, which lacks major histocompatibility class I (MHC-I) antigens and major histocompatibility class II (MHC-II) antigens and which has been modified to comprise and express (i) a nucleotide sequence encoding an **immunomodulator** and (ii) a nucleotide sequence encoding a viral antigen, and a method of inducing or stimulating an immune response in a human to a viral-associated disease or cancer comprising **administering** to the human (i) the aforementioned human cell line in an amount sufficient to induce or stimulate an immune response to the virus-associated disease or cancer, (ii) a human cell line, which lacks MHC-I and MHC-II antigens and which has been modified to comprise and express a nucleotide sequence encoding an **immunomodulator**, and a human cell line, which lacks MHC-I and MHC-II antigens and which has been modified to comprise and express a nucleotide sequence encoding an antigen of EBV, simultaneously or sequentially in either order, by the same or different routes, in amts. sufficient to induce or stimulate an immune response to the viral-associated disease or cancer, or (iii) an **immunomodulator** and a human cell line, which lacks MHC-I and MHC-II antigens and which has been modified to comprise and express a nucleotide sequence encoding an antigen of EBV, simultaneously or sequentially in either order, by the same or different routes, in amts. sufficient to induce or stimulate an immune response to the virus-associated disease or cancer. The **immunomodulator** is a cytokine (e.g. interleukin, interferon, TNF, GM-CSF, etc.), chemokine (e.g. MIP-1 α , MIP-1 β RANTES, Gro- α , Gro- β , etc.) or adjuvant (e.g. heat shock protein or **CpG**). The tumor-associated virus-derived antigen is Epstein-Barr virus-derived EBNA-1, LMP-1 and LMP-2.

L25 ANSWER 2 OF 39 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2004:252640 HCAPLUS

DOCUMENT NUMBER: 140:281354

TITLE: Antiviral random sequence oligonucleotides lacking complementarity to target genomes and their **therapeutic** uses

INVENTOR(S): Vaillant, Andrew; Juteau, Jean-Marc

PATENT ASSIGNEE(S): Replicor, Inc., Can.

SOURCE: PCT Int. Appl., 161 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004024919	A1	20040325	WO 2003-IB4573	20030911
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,			

TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
 CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
 NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
 GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-410264P P 20020913

US 2002-430934P P 20021205

AB Random sequence oligonucleotides that have antiviral activity are described, along with their use as antiviral agents. In many cases, the oligonucleotides are greater than 40 nucleotides in length. Also described are methods for the prophylaxis or **treatment** of a viral infection in a human or animal, and a method for the prophylaxis **treatment** of cancer caused by oncoviruses in a human or animal. The methods typically involve **administering** to a human or animal in need of such **treatment**, a pharmacol. acceptable, **therapeutically** effective amount of at least oligonucleotide that does not act by a sequence complementary mode of action. The selection of phosphorothioate oligonucleotides inhibiting the replication of human herpesvirus 1 in cell culture with IC50's of 0.043-0.059 μ M is reported. An oligonucleotide inhibiting the replication of the NL4-3 strain of human immunodeficiency virus 1 in 293A cells at an IC50 of 0.011 μ M is identified.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 3 OF 39 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2004:162782 HCAPLUS

DOCUMENT NUMBER: 140:216175

TITLE: Fc γ RIIB-specific antibodies and fragments for diagnosis and **treatment** of cancer, inflammation, autoimmune disease, allergy and immune disease

INVENTOR(S): Koenig, Scott; Veri, Maria-Concetta

PATENT ASSIGNEE(S): Macrogenics, Inc., USA

SOURCE: PCT Int. Appl., 174 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004016750	A2	20040226	WO 2003-US25399	20030814
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 2002-403266P P 20020814

AB The present invention relates to antibodies or fragments thereof that specifically bind Fc γ RIIB, particularly human Fc γ RIIB, with

greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The antibodies are humanized or chimeric derivs. of mouse monoclonal antibody 3H7 and 2B6. The invention provides methods of enhancing the **therapeutic** effect of **therapeutic** antibodies by **administering** the antibodies of the invention to enhance the effector function of the **therapeutic** antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by **administering** the antibodies of the invention.

L25 ANSWER 4 OF 39 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2004:60544 HCAPLUS

DOCUMENT NUMBER: 140:144682

TITLE: Molecular antigen arrays comprising AP205 virus-like particle and antigen for prevention and **treatment** of cancer, drug addiction, poisoning, infection, and allergy

INVENTOR(S): Bachmann, Martin F.; Tissot, Alain; Pumpens, Paul; Cielens, Indulis; Renhofa, Regina

PATENT ASSIGNEE(S): Cytos Biotechnology AG, Switz.

SOURCE: PCT Int. Appl., 170 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004007538	A2	20040122	WO 2003-EP7572	20030714
WO 2004007538	A3	20040304		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2004076611	A1	20040422	US 2003-617876	20030714

PRIORITY APPLN. INFO.: US 2002-396126P P 20020717

AB The present invention provides a composition comprising an AP205 virus like particle (VLP) and an antigen. The invention also provides a process for producing an antigen or antigenic determinant bound to AP205 VLP. AP205 VLP bound to an antigen is useful in the production of compns. for inducing immune responses that are useful for the prevention or **treatment** of diseases, disorders or conditions including infectious diseases, allergies, cancer, drug addiction, poisoning and to efficiently induce self-specific immune responses, in particular antibody responses.

L25 ANSWER 5 OF 39 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2004:60253 HCAPLUS

DOCUMENT NUMBER: 140:127195

TITLE: Antibodies specifically bind to anionic phospholipids and/or aminophospholipids conjugated with duramycin peptide for **treating** viral infections and

INVENTOR(S): cancer
Thorpe, Philip E.; Soares, Melina M.; Huang, Xianming;
He, Jin; Ran, Sophia
PATENT ASSIGNEE(S): Board of Regents the University of Texas System, USA
SOURCE: PCT Int. Appl., 378 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004006847	A2	20040122	WO 2003-US21925	20030715
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2002-396263P P 20020715

AB Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compns. and methods for utilizing these findings in the **treatment** of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compns. and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective **treatment** of cancer, viral infections and related diseases.

L25 ANSWER 6 OF 39 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2004:59558 HCAPLUS

DOCUMENT NUMBER: 140:127193

TITLE: Vaccines comprising aggregating protein epitopes and antibodies for **treating** a plaque-forming neurological or CNS disease

INVENTOR(S): Solomon, Beka; Frenkel, Dan

PATENT ASSIGNEE(S): Ramot At Tel-Aviv University Ltd., Israel

SOURCE: U.S. Pat. Appl. Publ., 68 pp., Cont.-in-part of U.S. Ser. No. 162,889.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004013647	A1	20040122	US 2003-384788	20030311
US 6703015	B1	20040309	US 1999-473653	19991229
WO 2001018169	A2	20010315	WO 2000-IL518	20000831
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,				

LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2002052311 A1 20020502 US 2001-808037 20010315
US 2003077252 A1 20030424 US 2002-162889 20020606
US 2004052766 A1 20040318 US 2003-618856 20030715

PRIORITY APPLN. INFO.:

US 1999-152417P P 19990903
US 1999-473653 B2 19991229
US 2000-629971 B2 20000731
WO 2000-IL518 W 20000831
US 2001-808037 B2 20010315
US 2001-830954 A2 20010807
US 2002-371735P P 20020412
US 2002-162889 A2 20020606

AB A method of immunizing against plaque forming diseases using display
technol. is provided. The method utilize novel agents, or pharmaceutical
compsns. for vaccination against plaque forming diseases which rely upon
presentation of an antigen or epitope on a display vehicle. The method
further includes agents, or pharmaceutical compsns. for vaccination against
plaque forming diseases, which rely upon presentation of an antibody, or
an active portion thereof, on a display vehicle. Whether antigens or
antibodies are employed, disaggregation of plaques results from the
immunization. The methods of the present invention also generally relates
to **treating** and/or diagnosing neurol. diseases and disorders of
the central nervous, regardless of whether the disease or disorder is
plaque-forming or non-plaque forming.

L25 ANSWER 7 OF 39 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:972220 HCAPLUS

DOCUMENT NUMBER: 140:24702

TITLE: Use of self-associating peptides derived from a
membrane translocating sequence to direct aggregation

INVENTOR(S): Koentgen, Frank

PATENT ASSIGNEE(S): Scogen Pty. Ltd., Australia

SOURCE: PCT Int. Appl., 219 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003102187	A1	20031211	WO 2003-AU667	20030530
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2004029179	A1	20040212	US 2003-449831	20030530

PRIORITY APPLN. INFO.: US 2002-384878P P 20020531
 OTHER SOURCE(S): MARPAT 140:24702

AB A method of building multi-subunit complexes of proteins, e.g. to improve the activity of a mol., or to combine individual activities of different mols., using peptides derived from self-coalescing elements to direct the formation of aggregates is described. The present invention also discloses such chimeric mols. per se and their use in **therapeutic**, prophylactic and chemical process applications. In particular, methods of inducing complex formation in the activation of B cells are described. The self-coalescing elements are derived from the membrane translocation sequences of of secreted proteins.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 8 OF 39 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:777111 HCAPLUS

DOCUMENT NUMBER: 139:286381

TITLE: Methods and compositions using trefoil peptides for **treating** dermal lesions

INVENTOR(S): Podolsky, Daniel K.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 16 pp., Cont.-in-part of U.S. Ser. No. 362,310.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 15

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003185839	A1	20031002	US 2003-434636	20030509
US 6221840	B1	20010424	US 1996-631469	19960412
WO 9738712	A1	19971023	WO 1997-US6004	19970411
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				

US 2003148949 A1 20030807 US 2002-266069 20021007

PRIORITY APPLN. INFO.: US 1996-631469 W 19960412

WO 1997-US6004 W 19970411

US 2001-327673P P 20011005

US 2002-266069 A2 20021007

US 2002-422708P P 20021031

US 2003-362310 A2 20030219

US 1991-655965 B2 19910214

US 1992-837192 B2 19920213

US 1993-37741 B2 19930325

US 1994-191352 B2 19940202

AB This invention features methods of **treating** and preventing damage to the epidermis and dermis by local **administration** of trefoil peptides. The trefoil peptide can be **administered** either alone or in combination with other **therapeutics** including antimicrobial agents, anti-inflammatory agents or, analgesics. The trefoil peptide is especially intestinal trefoil factor.

L25 ANSWER 9 OF 39 HCAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2003:757316 HCAPLUS
 DOCUMENT NUMBER: 139:271088
 TITLE: Methods and compositions with trefoil peptides for
treating vaginal, cervical, and uterine
 epithelial lesions
 INVENTOR(S): Podolsky, Daniel K.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 16 pp., Cont.-in-part of U.S.
 Ser. No. 362,310.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 15
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003181384	A1	20030925	US 2003-435406	20030509
US 6221840	B1	20010424	US 1996-631469	19960412
WO 9738712	A1	19971023	WO 1997-US6004	19970411

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
 DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT,
 RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN,
 AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB,
 GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN,
 ML, MR, NE, SN, TD, TG

US 2003105016	A1	20030605	US 2002-235238	20020905
PRIORITY APPLN. INFO.:			US 1996-631469	W 19960412
			WO 1997-US6004	W 19970411
			US 2001-317657P	P 20010906
			US 2002-235238	A2 20020905
			US 2002-422708P	P 20021031
			US 2003-362310	A2 20030219
			US 1991-655965	B2 19910214
			US 1992-837192	B2 19920213
			US 1993-37741	B2 19930325
			US 1994-191352	B2 19940202

AB This invention features methods of **treating** and preventing
 damage to the vaginal, cervical, and uterine epithelium by local
administration of trefoil peptides. The trefoil peptide can be
administered either alone or in combination with one or
therapeutic agents. Intestinal trefoil factor-containing douche,
 suppository tablet, and paste formulations are given.

L25 ANSWER 10 OF 39 HCAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2003:697032 HCAPLUS
 DOCUMENT NUMBER: 139:224391
 TITLE: Methods for targeted inhibition of replication or
 transcription by Anti-gene Lock oligonucleotides, and
 specific genotype-based cell killing, and
therapeutic applications
 INVENTOR(S): Eshleman, James R.; Parker, Antony R.
 PATENT ASSIGNEE(S): USA
 SOURCE: PCT Int. Appl., 103 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003072745	A2	20030904	WO 2003-US5789	20030224
WO 2003072745	A3	20040226		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-359116P P 20020222
 US 2002-359614P P 20020225
 US 2002-366674P P 20020322

AB An oligonucleotide based **therapeutic** strategy, called "Antigene Locks", is described which specifically kills cells based on their genotype. The strategy employs anti-gene lock oligonucleotides with arms and a backbone that are complementary to both strands of the gene target. There is mispairing between the terminal bases and the backbone in the antigene locks. Antigene Locks bind specifically to their gene targets in a sequence dependent fashion, intertwine with both strands of the target DNA and are irreversibly ligated ("locked"), thereby inhibiting DNA synthesis. One of preferred uses is manipulation of cell strains causing plasmids and episomes to be eliminated from cells. It was demonstrated that antigene lock **treatment** of episome bearing blue bacteria produced white colonies due to episome loss. When the target is integrated or present in the bacterial or human genome, they inhibit target DNA synthesis and selectively kill the majority of these cells. When transformed into a mixed population of cells, where only one cell type possesses the target, antigene locks selectively kill only the target bearing cell population. Antigene locks kill cells irresp. of their transcriptional status, and are active in both prokaryotic and eukaryotic cells. It was demonstrated that lacZ or proA directed antigene locks produced significant cell killing in a target gene-bearing Escherichia coli cell population. It was shown that Alu and HPV-E7 antigene locks kill cervical cancer cells.

L25 ANSWER 11 OF 39 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:656299 HCAPLUS

DOCUMENT NUMBER: 139:196254

TITLE: Vaccines comprising antigen arrays for **treating** allergic eosinophilic diseases

INVENTOR(S): Bachmann, Martin; Jennings, Gary; Sonderegger, Ivo

PATENT ASSIGNEE(S): Switz.

SOURCE: U.S. Pat. Appl. Publ., 150 pp., Cont.-in-part of U.S.

Ser. No. 50,902.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 9

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003157479	A1	20030821	US 2002-289454	20021107
US 2003175290	A1	20030918	US 2002-50902	20020118
WO 2002056905	A2	20020725	WO 2002-IB166	20020121
WO 2002056905	A3	20031009		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

US 2001-331045P	P	20011107
US 2002-50902	A2	20020118
WO 2002-IB166	A	20020121
US 2002-396636P	P	20020719
US 2001-262379P	P	20010119
US 2001-288549P	P	20010504
US 2001-326998P	P	20011005

AB The present invention is related to the fields of mol. biol., virol., immunol. and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array, and in particular an array comprising a protein or peptide of IL-5, IL-13 or eotaxin. More specifically, the invention provides a composition comprising a virus-like particle and at least one protein, or peptide of IL-5, IL-13 and/or eotaxin bound thereto. The invention also provides a process for producing the conjugates and the ordered and repetitive arrays, resp. The compns. of the invention are useful in the production of vaccines for the **treatment** of allergic diseases with an eosinophilic component and as a pharmaccine to prevent or cure allergic diseases with an eosinophilic component and to efficiently induce immune responses, in particular antibody responses. Furthermore, the compns. of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context.

L25 ANSWER 12 OF 39 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:633886 HCAPLUS

DOCUMENT NUMBER: 139:196249

TITLE: Chimeric nucleic acid encoding CD1-derived endosomal targeting proteins for inducing MHC class II-mediated antigen presentation and for **treating** infection, autoimmune disease and cancer

INVENTOR(S): Modlin, Robert L.

PATENT ASSIGNEE(S): The Regents of the University of California, USA

SOURCE: PCT Int. Appl., 114 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO.2003066820 A2 20030814 WO 2003-US3550 20030205
 WO 2003066820 A3 20031113

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD,
 RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
 CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
 NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
 ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-355432P P 20020205

AB The present invention provides chimeric nucleic acid mols. encoding CD1 fusion proteins, comprising a leader peptide sequence, a CD1 endosomal targeting sequence, and an antigen of interest. In the CD1 fusion protein, the leader peptide sequence and CD1 endosomal targeting sequence direct production, processing, trafficking, and cell surface presentation of the antigen of interest via the MHCII antigen presenting pathway. The invention also provides methods for producing the CD1 fusion protein or the antigen of interest or fragments thereof, methods for targeting the antigen of interest to the MHCII antigen presenting pathway, and methods for presenting on a cell the antigen of interest. Addnl., the present invention provides methods for inducing in a subject an immune response mediated by a CD1 endosomal targeting sequence, methods for inducing in a subject an immune response to an antigen of interest, and methods for inducing in a subject an immune response mediated by an MHCII antigen presenting pathway.

L25 ANSWER 13 OF 39 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:524031 HCAPLUS

DOCUMENT NUMBER: 139:83965

TITLE: **Immunostimulatory** oligonucleotides and antigens for screening immunostimulants and for treating cancer, allergy and infections

INVENTOR(S): Raz, Eyal; Roman, Mark; Dina, Dino

PATENT ASSIGNEE(S): Dynavax Technologies Corporation, USA

SOURCE: U.S., 44 pp., Cont.-in-part of U.S. Ser. No. 92,329, abandoned.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6589940	B1	20030708	US 1999-296477	19990422
EP 1374894	A2	20040102	EP 2003-20257	19980605
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
US 2002086839	A1	20020704	US 2001-770943	20010125
US 2004006034	A1	20040108	US 2003-413504	20030411

PRIORITY APPLN. INFO.:

US 1997-48793P	P	19970606
US 1998-92329	B2	19980605
EP 1998-926311	A3	19980605
US 1998-92314	A1	19980605
US 1999-296477	A1	19990422

AB The invention relates to **immunostimulatory** oligonucleotide compns. These oligonucleotides comprise an **immunostimulatory** octanucleotide sequence. These oligonucleotides can be administered in conjunction with an **immunostimulatory** peptide or antigen. Methods for modulating an immune response upon administration of the oligonucleotide are also disclosed. In addition, an in vitro screening method to identify oligonucleotides with **immunostimulatory** activity is provided.

REFERENCE COUNT: 241 THERE ARE 241 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 14 OF 39 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:133429 HCAPLUS

DOCUMENT NUMBER: 138:210275

TITLE: **Immunomodulatory** compositions, formulations, and methods for use thereof

INVENTOR(S): Fearon, Karen L.; Dina, Dino

PATENT ASSIGNEE(S): Dynavax Technologies Corporation, USA

SOURCE: PCT Int. Appl., 79 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003014316	A2	20030220	WO 2002-US25123	20020807
WO 2003014316	A3	20040311		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003133988	A1	20030717	US 2002-214799	20020807
PRIORITY APPLN. INFO.:			US 2001-310743P	P 20010807
			US 2001-335263P	P 20011025

OTHER SOURCE(S): MARPAT 138:210275

AB The invention provides new compns. and methods for **immunomodulation** of individuals. **Immunomodulation** is accomplished by **administration** of **immunomodulatory** polynucleotide/microcarrier (IMO/MC) complexes comprising 3-6mer **immunomodulatory** oligonucleotides. The IMO/MC complexes may be covalently or non-covalently bound. Also provided are **immunomodulatory** compns. comprising a 3-6mer IMO encapsulated in an MC.

L25 ANSWER 15 OF 39 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:97913 HCAPLUS

DOCUMENT NUMBER: 138:147704

TITLE: Synthetic pre-trans-splicing molecules (PTM) encoding diphtheria toxin subunit A used for double RNA

trans-splicing to disrupt human **papillomavirus**
 virus 16 genes for cervix carcinoma **treatment**
 INVENTOR(S): Mitchell, Lloyd G.; Garcia-Blanco, Mariano A.; Baker,
 Carl C.; Puttaraju, Madaiah
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 124 pp., Cont.-in-part of U.S.
 Ser. No. 838,858.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 11
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003027250	A1	20030206	US 2001-941492	20010829
CA 2240494	AA	19970626	CA 1996-2240494	19961213
US 6013487	A	20000111	US 1996-766354	19961213
US 6083702	A	20000704	US 1998-133717	19980813
US 6280978	B1	20010828	US 1998-158863	19980923
US 2003077754	A1	20030424	US 2001-756096	20010108
US 2003148937	A1	20030807	US 2001-838858	20010420
WO 2002053581	A2	20020711	WO 2002-US416	20020108
WO 2002053581	A3	20020926		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,				
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL,				
PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,				
UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,				
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,				
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1358203	A2	20031105	EP 2002-714709	20020108
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2002193580	A1	20021219	US 2002-76248	20020212
PRIORITY APPLN. INFO.:				
			US 1995-8717P	P 19951215
			US 1996-766354	A2 19961213
			US 1998-87233	B2 19980528
			US 1998-133717	A2 19980813
			US 1998-158863	A2 19980923
			US 2001-756096	A2 20010108
			US 2001-838858	A2 20010420
			US 2001-756095	A 20010108
			US 2001-756097	A 20010108
			US 2001-941492	A 20010829
			WO 2002-US416	W 20020108
AB	The mols. and methods of the present invention provide a means for in vivo production of a trans-spliced mol. in a selected subset of cells. The pre-trans-splicing mols. of the invention are substrates for a trans-splicing reaction between the pre-trans-splicing mols. and a pre-mRNA which is uniquely expressed in the specific target cells. The in vivo trans-splicing reaction provides a novel mRNA which is functional as mRNA or encodes a protein to be expressed in the target cells. The synthetic PTMs are designed to interact with a natural target precursor mRNA mol. (target pre-mRNA) and mediate a trans-splicing reaction resulting in the generation of a novel chimeric RNA mol. (chimeric RNA). In addition, double trans-splicing reactions are used for the selective			

expression of a toxin in tumor cells. For example, PTMs are designed to replace the second exon of the human 1-chronic gonadotropin-6 (fhCG6) gene transcripts and to deliver an exon encoding the subunit A of diphtheria toxin (DT-A). Expression of DT-A in the absence of subunit B should lead to toxicity only in the cells expressing the gene. PTMs are also designed to target genes in human **Papillomavirus** type 16, like E2 to eliminate E2 function in DNA replication, and demonstrated to express diphtheria toxin sub unit A (DT-A) product, which will kill the infected cells or express a marker gene which can be easily detected. The expression product of the mRNA is a protein of **therapeutic** value to the cell or host organism a toxin which causes killing of the specific cells or a novel protein not normally present in such cells. Other gene repair models for CFTR, or chorionic gonadotropin gene β HCG6 or β -galactosidase reporter gene, or mouse factor VIII gene are also designed and demonstrated. The invention further provides PTMs that have been genetically engineered for the identification of exon/intron boundaries of pre-mRNA mols. using an exon tagging method. The PTMs of the invention can also be designed to result in the production of chimeric RNA encoding for peptide affinity purification tags which can be used to purify and identify proteins expressed in a specific cell type.

L25 ANSWER 16 OF 39 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:77776 HCAPLUS

DOCUMENT NUMBER: 138:135200

TITLE: Genes, gene products, and alleles associated with a predisposition to infection by human **papilloma** virus, epidermodysplasia verruciformis or psoriasis
 INVENTOR(S): Orth, Gerard; Favre, Michel; Ramoz, Nicolas
 PATENT ASSIGNEE(S): Institut Pasteur, Fr.; Institut National de la Sante et de la Recherche Medicale (INSERM)

SOURCE: Eur. Pat. Appl., 56 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1279733	A1	20030129	EP 2001-401993	20010724
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.: EP 2001-401993 20010724

AB Two new genes, Evin-1 and Evin-2, found in the epidermodysplasia verruciformis locus of the human genome, alleles of the gene, and their gene products that appear to be involved in the susceptibility to infection with Human **Papilloma** Virus (HPV), epidermodysplasia verruciformis (EV), or to psoriasis are described. The invention also relates to the use of Evin-1 and Evin-2 genes and their expression products or fragments thereof for the diagnosis of a susceptibility to HPV, to EV and/or to psoriasis. Finally, the invention relates to pharmaceutical compns. comprising Evin-1 or Evin-2 derived nucleic acids and to the screening of new drugs for the **treatment** or the prevention of infection to HPV, EV and/or psoriasis.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 17 OF 39 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:5800 HCAPLUS

DOCUMENT NUMBER: 138:71905
TITLE: Methods of inducing a cytotoxic immune response using recombinant simian adenovirus vectors
INVENTOR(S): Ertl, Hildegund C. J.; Wilson, James M.
PATENT ASSIGNEE(S): The Wistar Institute of Anatomy and Biology, USA; The Trustees of the University of Pennsylvania
SOURCE: PCT Int. Appl., 75 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003000283	A1	20030103	WO 2002-US15239	20020513
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1409012	A1	20040421	EP 2002-780874	20020513
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
PRIORITY APPLN. INFO.:			US 2001-300131P	P 20010622
			US 2001-304843P	P 20010712
			WO 2002-US15239	W 20020513
AB	A method of inducing a CD8+ T response against a selected mol. by delivering the mol. via a recombinant simian adenovirus is provided. Also provided are methods of inducing interferon- α and interferon- β by delivering a recombinant simian adenovirus to a subject. The methods and compns. of the invention are particularly well suited for prophylaxis and treatment of infections with human immunodeficiency virus and human papilloma virus, among others, and cancer therapy .			
REFERENCE COUNT:	4	THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		

L25 ANSWER 18 OF 39 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:716292 HCAPLUS
DOCUMENT NUMBER: 137:243710
TITLE: Identification, cloning, characterization and use of human mitochondrial apoptosis modulator protein Bcl-B
INVENTOR(S): Reed, John C.; Ke, Ning; Godzik, Adam
PATENT ASSIGNEE(S): The Burnham Institute, USA
SOURCE: PCT Int. Appl., 82 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 2002072601 A2 20020919 WO 2002-US3547 20020207
 WO 2002072601 A3 20040401

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
 HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
 LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO,
 RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,
 VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003176671 A1 20030918 US 2002-71174 20020207
 PRIORITY APPLN. INFO.: US 2001-267166P P 20010207
 US 2002-71174 A 20020207

AB A novel human member of the Bcl-2 Family Bcl-B has been identified, which is closest in amino-acid sequence homol. to the Boo (Diva) protein. The cDNA sequence and the encoded amino acid sequence of the human Bcl-B protein are disclosed. The Bcl-B protein is widely expressed in adult human tissues. The Bcl-B protein assoc. with mitochondria. The Bcl-B protein modulates apoptosis. Bcl-B also binds Bcl-2, Bcl-XL, and Bax but not Bak. Bcl-B displays a unique pattern of selectivity for binding and regulating the function of other members of the Bcl-2 family.

L25 ANSWER 19 OF 39 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:595035 HCAPLUS

DOCUMENT NUMBER: 137:168254

TITLE: Superior molecular vaccine based on self-replicating RNA, suicidal DNA or naked DNA vector, that links antigen with polypeptide that promotes antigen presentation for **treating** cancer and infections

INVENTOR(S): Wu, Tzyy-Choou; Hung, Chien-Fu
 PATENT ASSIGNEE(S): The Johns Hopkins University, USA
 SOURCE: PCT Int. Appl., 127 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002061113	A2	20020808	WO 2002-US2598	20020201
WO 2002061113	A3	20021212		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
 TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1363660 A2 20031126

EP 2002-707618 20020201

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRIORITY APPLN. INFO.: US 2001-265334P P 20010201
 WO 2002-US2598 W 20020201

AB Improved mol. vaccines comprise nucleic acid vectors that encode a fusion polypeptide that includes polypeptide or peptide phys. linked to an antigen. The linked polypeptide is one that (a) promotes processing of the expressed fusion polypeptide via the MHC class I pathway and/or (b) promotes development or activity of antigen presenting cells, primarily dendritic cells. These vaccines employ one of several types of nucleic acid vectors, each with its own relative advantages: naked DNA plasmids, self-replicating RNA replicons and suicidal DNA-based on viral RNA replicons. **Administration** of such a vaccine results in enhance immune responses, primarily those mediated by CD8+ cytotoxic T lymphocytes, directed against the immunizing antigen part of the fusion polypeptide. Such vaccines are useful against tumor antigens, viral antigens and antigens of other pathogenic microorganisms and can be used in the prevention or **treatment** of diseases that include cancer and infections.

L25 ANSWER 20 OF 39 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:555369 HCAPLUS

DOCUMENT NUMBER: 137:124189

TITLE: Vaccine compositions comprising molecular antigen array against cancer, infection, and allergy

INVENTOR(S): Renner, Wolfgang A.; Bachmann, Martin; Tissot, Alain; Maurer, Patrick; Lechner, Franziska; Sebbel, Peter; Piossek, Christine

PATENT ASSIGNEE(S): Cytos Biotechnology A.-G., Switz.

SOURCE: PCT Int. Appl., 442 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 9

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002056905	A2	20020725	WO 2002-IB166	20020121
WO 2002056905	A3	20031009		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2003175711	A1	20030918	US 2002-50898	20020118
EP 1370290	A2	20031217	EP 2002-710211	20020121
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
BR 2002006566	A	20040127	BR 2002-6566	20020121
WO 2003031466	A2	20030417	WO 2002-EP11219	20021007
WO 2003031466	A3	20031023		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD,			

RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
 CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
 PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
 NE, SN, TD, TG
 WO 2003039225 A2 20030515 WO 2002-EP12449 20021107
 WO 2003039225 A3 20040304
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT,
 TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ,
 MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
 CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
 PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
 NE, SN, TD, TG
 WO 2003040164 A2 20030515 WO 2002-EP12455 20021107
 WO 2003040164 A3 20031023
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT,
 TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ,
 MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
 CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
 PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
 NE, SN, TD, TG
 US 2003157479 A1 20030821 US 2002-289454 20021107
 US 2004033211 A1 20040219 US 2002-289456 20021107
 WO 2003059386 A2 20030724 WO 2003-EP460 20030117
 WO 2003059386 A3 20040311
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD,
 RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
 CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
 NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
 ML, MR, NE, SN, TD, TG
 US 2003219459 A1 20031127
 US 2001-262379P P 20010119
 US 2001-288549P P 20010504
 US 2001-326998P P 20011005
 US 2001-331045P P 20011107
 US 2002-50902 A 20020118
 WO 2002-IB166 W 20020121
 US 2002-393725P P 20020708
 US 2002-396590P P 20020718
 US 2002-396635P P 20020719
 US 2002-396636P P 20020719
 US 2002-396637P P 20020719

AB The present invention is related to the fields of mol. biol., virol.,

immunol. and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The ordered and repetitive antigen or antigenic determinant is useful in the production of vaccines for the **treatment** of infectious diseases, the **treatment** of allergies and as a pharmaccine to prevent or cure cancer and to efficiently induce self-specific immune responses, in particular antibody responses.

L25 ANSWER 21 OF 39 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:521768 HCAPLUS

DOCUMENT NUMBER: 137:89415

TITLE: **Therapeutic** pre-mRNAs for use in spliceosome-mediated RNA trans-splicing in the **treatment** of genetic diseases

INVENTOR(S): Mitchell, Lloyd G.; Garcia-Blanco, Mariano A.; Baker, Carl C.; Puttaraju, Madaiah; Mansfield, Gary S.; Chao, Hengjun

PATENT ASSIGNEE(S): Intronn, Inc., USA

SOURCE: PCT Int. Appl., 229 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 11

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002053581	A2	20020711	WO 2002-US416	20020108
WO 2002053581	A3	20020926		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2002115207	A1	20020822	US 2001-756095	20010108
US 2003077754	A1	20030424	US 2001-756096	20010108
US 2003148937	A1	20030807	US 2001-838858	20010420
US 2003027250	A1	20030206	US 2001-941492	20010829
EP 1358203	A2	20031105	EP 2002-714709	20020108
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
PRIORITY APPLN. INFO.:			US 2001-756095	A 20010108
			US 2001-756096	A 20010108
			US 2001-756097	A 20010108
			US 2001-838858	A 20010420
			US 2001-941492	A 20010829
			US 1995-8717P	P 19951215
			US 1996-766354	A2 19961213
			US 1998-87233	B2 19980528
			US 1998-133717	A2 19980813
			US 1998-158863	A2 19980923
			WO 2002-US416	W 20020108

AB The mols. and methods of the present invention provide a means for in vivo

production of a trans-spliced mol. in a selected subset of cells. The pre-trans-splicing mols. of the invention are substrates for a trans-splicing reaction between the pre-trans-splicing mols. and a pre-mRNA which is uniquely expressed in the specific target cells. The in vivo trans-splicing reaction provides a novel mRNA which is functional as mRNA or encodes a protein to be expressed in the target cells. The expression product of the mRNA is a protein of **therapeutic** value to the cell or host organism a toxin which causes killing of the specific cells or a novel protein not normally present in such cells. The invention further provides PTMs that have been genetically engineered for the identification of exon/intron boundaries of pre-mRNA mols. using an exon tagging method. The PTMs of the invention can also be designed to result in the production of chimeric RNA encoding for peptide affinity purification tags which can be used to purify and identify proteins expressed in a specific cell type.

L25 ANSWER 22 OF 39 HCAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2002:131538 HCAPLUS
 DOCUMENT NUMBER: 136:182456
 TITLE: DNA vaccine for inducing mucosal immunity
 INVENTOR(S): Weiner, David B.; Wang, Bin; Ugen, Kenneth E.
 PATENT ASSIGNEE(S): The Trustees of the University of Pennsylvania, USA
 SOURCE: U.S., 31 pp., Cont.-in-part of U.S. 5,593,972.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6348449	B1	20020219	US 1994-357398	19941216
US 5593972	A	19970114	US 1993-125012	19930921
CA 2208524	AA	19960620	CA 1995-2208524	19951215
WO 9618390	A1	19960620	WO 1995-US16206	19951215
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9645169	A1	19960703	AU 1996-45169	19951215
AU 701208	B2	19990121		
EP 796104	A1	19970924	EP 1995-943781	19951215
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
US 2002142987	A1	20021003	US 2002-76900	20020214
PRIORITY APPLN. INFO.:				
			US 1993-125012	A2 19930921
			US 1993-8342	B2 19930126
			US 1993-29336	B2 19930311
			US 1994-357398	A 19941216
			WO 1995-US16206	W 19951215

AB Methods of inducing mucosal immunity in individuals against proteins and peptides are disclosed. The methods comprise the step of **administering** topically or by lavage into mucosal tissue selected from the group consisting of rectal, vaginal, urethral, sublingual and buccal, a nucleic acid mol. that comprises a nucleotide sequence that encodes a protein or peptide that comprises an epitope against which

mucosal immunity is desired. The methods may be used to immunize an individual against a pathogen infection, hyperproliferative diseases or autoimmune diseases using nucleic acid mols. which encode proteins and peptides that share an epitope with a pathogen antigen or protein associated with cells involved in hyperproliferative diseases or autoimmune diseases, resp.

REFERENCE COUNT: 76 THERE ARE 76 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 23 OF 39 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:833125 HCAPLUS

DOCUMENT NUMBER: 136:4705

TITLE: Molecular antigen array

INVENTOR(S): Sebbel, Peter; Dunant, Nicolas; Bachmann, Martin; Tissot, Alain; Lechener, Franziska

PATENT ASSIGNEE(S): Cytos Biotechnology A.-G., Switz.

SOURCE: PCT Int. Appl., 287 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001085208	A2	20011115	WO 2001-IB741	20010502
WO 2001085208	A3	20020523		
WO 2001085208	C1	20020919		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1278542	A2	20030129	EP 2001-925778	20010502
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2003054010	A1	20030320	US 2001-848616	20010504
PRIORITY APPLN. INFO.: US 2000-202341P P 20000505				
WO 2001-IB741 W 20010502				

AB The invention provides compns. and processes for the production of ordered and repetitive antigen or antigenic determinant arrays. The compns. of the invention are useful for the production of vaccines for the prevention of infectious diseases, the **treatment** of allergies and the **treatment** of cancers. Various embodiments of the invention provide for a core particle that is coated with any desired antigen in a highly ordered and repetitive fashion as the result of specific interactions.

L25 ANSWER 24 OF 39 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:772080 HCAPLUS

DOCUMENT NUMBER: 135:330476

TITLE: Variants of human **papilloma** virus antigens

INVENTOR(S): Edwards, Stirling John; Cox, John Cooper; Webb, Elizabeth Ann; Frazer, Ian

PATENT ASSIGNEE(S): Csl Ltd., Australia; The University of Queensland

SOURCE: U.S., 28 pp., Cont.-in-part of U.S. Ser. No. 860,165.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6306397	B1	20011023	US 1999-359382	19990723
CA 2419289	AA	19960627	CA 1995-2419289	19951220
WO 9619496	A1	19960627	WO 1995-AU868	19951220
W: AU, CA, JP, NZ, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 6004557	A	19971221	US 1997-860165	19970922
PRIORITY APPLN. INFO.:				
			AU 1994-157	A 19941220
			WO 1995-AU868	W 19951220
			US 1997-860165	A2 19970922
			CA 1995-2207741	A3 19951220
AB Variants of human papilloma virus (HPV) E6 and E7 proteins able to elicit a humoral and/or cellular immune response against HPV in a host animal but not being cell-transforming in the host animal are disclosed, and are useful in treatment or prevention of diseases or conditions involving HPV.				
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT				

L25 ANSWER 25 OF 39 HCAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2001:693111 HCAPLUS
 DOCUMENT NUMBER: 135:267201
 TITLE: Methods of reducing **papillomavirus** infection using **immunomodulatory** polynucleotide sequences
 INVENTOR(S): Van Nest, Gary
 PATENT ASSIGNEE(S): Dynavax Technologies Corporation, USA
 SOURCE: PCT Int. Appl., 44 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001068117	A2	20010920	WO 2001-US7842	20010312
WO 2001068117	A3	20020808		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002107212	A1	20020808	US 2001-802445	20010309
EP 1261353	A2	20021204	EP 2001-916582	20010312
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

JP.2003526673 T2 20030909 JP 2001-566681 20010312
 PRIORITY APPLN. INFO.: US 2000-188265P P 20000310
 US 2001-802445 A 20010309
 WO 2001-US7842 W 20010312

AB The invention provides methods for the **treatment** of **papillomavirus** infections. A polynucleotide comprising an **immunostimulatory** sequence is **administered** to an individual who has been exposed to or infected by **papillomavirus**. The polynucleotide is not **administered** with **papillomavirus** antigen. **Administration** of the polynucleotide results in amelioration of symptoms of **papillomavirus** infection.

L25 ANSWER 26 OF 39 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:693074 HCAPLUS

DOCUMENT NUMBER: 135:267226

TITLE: Methods of preventing and **treating** viral infections and using **immunomodulatory** polynucleotide sequences

INVENTOR(S): **Van Nest, Gary**

PATENT ASSIGNEE(S): Dynavax Technologies Corporation, USA

SOURCE: PCT Int. Appl., 65 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001068077	A2	20010920	WO 2001-US7840	20010312
WO 2001068077	A3	20020808		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 2002028784	A1	20020307	US 2001-802685	20010309
EP 1267893	A2	20030102	EP 2001-918567	20010312
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2003535043	T2	20031125	JP 2001-566641	20010312
PRIORITY APPLN. INFO.:			US 2000-188302P P	20000310
			US 2001-802685 A	20010309
			WO 2001-US7840 W	20010312

AB The invention provides methods of suppression, prevention, and/or **treatment** of infection by viruses. A polynucleotide comprising an **immunostimulatory** sequence (an "ISS") is **administered** to an individual who is at risk of being exposed to, has been exposed to or is infected with a virus. The **ISS**-containing polynucleotide is **administered** without any antigens of the virus. **Administration** of the **ISS**-containing polynucleotide results in reduced incidence and/or severity of one or more symptoms of virus infection.

L25 ANSWER 27 OF 39 HCAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2001:435369 HCAPLUS
 DOCUMENT NUMBER: 135:56914
 TITLE: Nucleic acid compositions, kits, and methods for
 identification, assessment, prevention, and therapy of
 human cervical cancer
 INVENTOR(S): Schlegel, Robert; Deeds, James; Berger, Allison; Zhao,
 Xumei
 PATENT ASSIGNEE(S): Millennium Predictive Medicine, Inc., USA
 SOURCE: PCT Int. Appl., 436 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001042792	A2	20010614	WO 2000-US33311	20001208
WO 2001042792	A3	20020131		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
 HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
 LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
 SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
 ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2002009724	A1	20020124	US 2000-732560	20001208
PRIORITY APPLN. INFO.:		US 1999-169811P	P	19991208
		US 1999-171330P	P	19991221
		US 2000-189113P	P	20000314
		US 2000-193943P	P	20000331
		US 2000-203772P	P	20000512
		US 2000-210820P	P	20000609
		US 2000-220113P	P	20000721

AB The invention relates to nucleic acid compns., kits, and methods for
 detecting, characterizing, preventing, and treating cervical cancers. A
 variety of markers (7280 different GenBank Accession Nos.) are provided,
 wherein changes in the levels of expression of one or more of the markers
 is correlated with the presence of cervical cancer.

L25 ANSWER 28 OF 39 HCAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2001:247202 HCAPLUS
 DOCUMENT NUMBER: 134:279560
 TITLE: Methods related to **immunostimulatory** nucleic
 acid-induced interferon
 INVENTOR(S): Hartmann, Gunther; Bratzler, Robert L.; Krieg, Arthur
 PATENT ASSIGNEE(S): Coley Pharmaceutical Group, Inc., USA; University of
 Iowa Research Foundation
 SOURCE: PCT Int. Appl., 168 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

 WO 2001022990 A2 20010405 WO 2000-US26527 20000927
 WO 2001022990 A3 20011004

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
 HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
 LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
 SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
 ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
 CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1220684 A2 20020710 EP 2000-965477 20000927

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL

JP 2003510290 T2 20030318 JP 2001-526199 20000927

ZA 2002001959 A 20030310 ZA 2002-1959 20020308

PRIORITY APPLN. INFO.:

US 1999-156147P P 19990927

WO 2000-US26527 W 20000927

AB Methods and compns. are provided for extending the clin. utility of
 IFN- α in the **treatment** of a variety of viral and
 proliferative disorders. Among other aspects, the invention provides
 methods which increase the efficacy of IFN- α **treatment** and
 reduce IFN- α **treatment**-related side effects. In addition,
 methods are provides for supporting the survival and for activating
 natural interferon producing cells (IPCs) in vitro without exogenous IL-3
 or GM-CSF. The invention is based on the discovery that certain
CpG and non-**CpG** ISNAs promote survival and stimulation
 of IPCs.

L25 ANSWER 29 OF 39 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:45169 HCAPLUS

DOCUMENT NUMBER: 134:110441

TITLE: Antisense oligonucleotide inhibition of
papillomavirus

INVENTOR(S): Crooke, Stanley T.; Mirabelli, Christopher K.; Ecker,
 David J.; Cowser, Lex M.

PATENT ASSIGNEE(S): Isis Pharmaceuticals, Inc., USA

SOURCE: U.S., 36 pp., Cont.-in-part of U.S. 5,811,232.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6174870	B1	20010116	US 1998-130426	19980806
US 5811232	A	19980922	US 1996-692257	19960805
PRIORITY APPLN. INFO.:				
			US 1989-445196	B2 19891204
			US 1996-692257	A2 19960805
			US 1992-835946	B1 19920303

AB Oligonucleotides and oligonucleotide analogs are provided which are
 capable of antisense interaction with mRNA of **papillomavirus**.
 Such oligonucleotides or oligonucleotide analogs can be used for
 diagnostics and **therapeutics**, as well as for research purposes.
 In accordance with preferred embodiments of the invention, an
 oligonucleotide or oligonucleotide analog is provided which is
 hybridizable with a mRNA from a **papillomavirus**. The

oligonucleotide or oligonucleotide analog is able to inhibit the function of the RNA and is useful for **therapy** for infections by **papillomavirus**. In accordance with a preferred embodiment, portions of the **papillomavirus** are targeted for antisense attack. Thus oligonucleotides are preferably provided which hybridize with the E2, E1, E7, E6 or E6-7 mRNAs.

REFERENCE COUNT: 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 30 OF 39 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2000:383970 HCAPLUS

DOCUMENT NUMBER: 133:42164

TITLE: Ordered molecular presentation of antigens on virus-like particles

INVENTOR(S): Renner, Wolfgang A.; Hennecke, Frank; Nieba, Lars; Bachmann, Martin

PATENT ASSIGNEE(S): Cytos Biotechnology A.-G., Switz.

SOURCE: PCT Int. Appl., 102 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000032227	A2	20000608	WO 1999-IB1925	19991130
WO 2000032227	A3	20001012		
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1135162	A2	20010926	EP 1999-972928	19991130
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
BR 9915771	A	20011226	BR 1999-15771	19991130
NZ 512456	A	20031031	NZ 1999-512456	19991130
AU 768807	B2	20040108	AU 2000-14020	19991130
ZA 2001005050	A	20020620	ZA 2001-5050	20010620
PRIORITY APPLN. INFO.:			US 1998-110414P P	19981130
			US 1999-142788P P	19990708
			WO 1999-IB1925 W	19991130

AB The authors disclose the preparation of ordered arrays of antigens or antigenic determinants. The ordered arrays are provide for by covalent and non-covalent association of antigens with recombinant viruses, virus-like particles (envelope and capsid), bacteriophage or other carriers. In one specific embodiment, a versatile new technol. based on a cassette-type system (alphavirus) allows production of antigen coated viral particles. Other specific embodiments allow the production of antigen coated hepatitis B virus-like particles or antigen coated measles virus-like particles.

L25 ANSWER 31 OF 39 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1998:813720 HCAPLUS

DOCUMENT NUMBER: 130:65226

TITLE: **Immunostimulatory** oligonucleotides,
compositions thereof and methods of use thereof
INVENTOR(S): Schwartz, David; Roman, Mark; Dina, Dino
PATENT ASSIGNEE(S): Dynavax Technologies Corp., USA
SOURCE: PCT Int. Appl., 63 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9855495	A2	19981210	WO 1998-US11578	19980605
WO 9855495	A3	19990527		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9878178	A1	19981221	AU 1998-78178	19980605
AU 753172	B2	20021010		
EP 986572	A2	20000322	EP 1998-926311	19980605
EP 986572	B1	20031022		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
US 6225292	B1	20010501	US 1998-92314	19980605
JP 2002517156	T2	20020611	JP 1999-502884	19980605
AT 252596	E	20031115	AT 1998-926311	19980605
EP 1374894	A2	20040102	EP 2003-20257	19980605
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
US 2002086839	A1	20020704	US 2001-770943	20010125
PRIORITY APPLN. INFO.:				
			US 1997-48793P	P 19970606
			EP 1998-926311	A3 19980605
			US 1998-92314	A1 19980605
			WO 1998-US11578	W 19980605

AB The invention relates to **immunostimulatory** oligonucleotide compns. These oligonucleotides comprise an **immunostimulatory** octanucleotide sequence. These oligonucleotides can be **administered** in conjunction with an **immunostimulatory** peptide or antigen. Methods for modulating an immune response upon **administration** of the oligonucleotide are also disclosed. In addition, an in vitro screening method to identify oligonucleotides with **immunostimulatory** activity is provided. Compns. containing the **immunostimulatory** oligonucleotide, antigen, adjuvant and co-stimulatory mol. (e.g. cytokine) are useful for **treating** cancer, allergy, asthma, viral infection, bacterial infection, and parasitic infection.

L25 ANSWER 32 OF 39 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1998:331520 HCAPLUS
DOCUMENT NUMBER: 129:12732
TITLE: Antisense oligonucleotide to **papillomavirus**
for diagnosis and **treatment** of infection
INVENTOR(S): Crooke, Stanley T.; Mirabelli, Christopher K.; Ecker,

PATENT ASSIGNEE(S): David J.; Cowsert, Lex M.
 SOURCE: Isis Pharmaceuticals, Inc., USA
 U.S., 36 pp., Cont.-in-part of U.S. 5,457,189.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 5
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5756282	A	19980526	US 1995-370517	19950109
US 5457189	A	19951010	US 1992-860925	19920331
PRIORITY APPLN. INFO.:			US 1989-445196	B2 19891204
			US 1992-860925	A2 19920331

AB Oligonucleotides are provided which are capable of antisense interaction with mRNA of **papillomavirus**. Such oligonucleotides or oligonucleotide analogs can be used for diagnostics and **therapeutics** as well as for research purposes. In accordance with preferred embodiments of this invention, oligonucleotide ISIS 2105 is provided which hybridizes with selected mRNA from a human **papillomavirus**. The oligonucleotide is able to inhibit the function of the RNA, and accordingly is useful for **therapy** for infections by such **papillomavirus**. In accordance with a preferred embodiment, portions of the **papillomavirus** are targeted for antisense attack. Thus, oligonucleotides are preferably provided which hybridize with the E2 transactivator mRNA.

REFERENCE COUNT: 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 33 OF 39 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1996:616379 HCAPLUS

DOCUMENT NUMBER: 125:238677

TITLE: Human **papillomavirus** proteins as immunostimulants and vaccines, especially gene L2-E7 fusion protein recombinant production and **wart treatment**

INVENTOR(S): Whittle, Nigel Richard; Carmichael, Jeremy Paddon; Connor, Stephen Edward; Thompson, Henry Stephen Grammer; Wilson, Mark Jonathan

PATENT ASSIGNEE(S): Cantab Pharmaceuticals Research Limited, UK

SOURCE: PCT Int. Appl., 44 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9626277	A1	19960829	WO 1996-GB397	19960223
W: AU, CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2211995	AA	19960829	CA 1996-2211995	19960223
AU 9647272	A1	19960911	AU 1996-47272	19960223
EP 812358	A1	19971217	EP 1996-903127	19960223
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
JP 11501804	T2	19990216	JP 1996-525496	19960223
US 5955087	A	19990921	US 1996-606288	19960223

US 6123948 A 20000926 US 1999-347483 19990702
 AU 9944544 A1 19991021 AU 1999-44544 19990817
 PRIORITY APPLN. INFO.:

GB 1995-3786 A 19950224
 US 1995-34P P 19950608
 GB 1995-15478 A 19950728
 AU 1996-47272 A3 19960223
 US 1996-606288 A1 19960223
 WO 1996-GB397 W 19960223

AB Fusion polypeptides and aggregates of polypeptides comprising
papillomavirus-derived antigens, and compns. thereof and their use
 e.g. with adjuvants for immunogenic and vaccine purposes in eliciting e.g.
 HPV-specific immune responses. The polypeptides can be purified to result
 in aggregates which when in solution or dispersion can pass through a
 sterilization filter, and in amorphous aggregates. An example of such a
 polypeptide is a fusion protein of human **papillomavirus** proteins
 L2 and E7.

L25 ANSWER 34 OF 39 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1995:913776 HCAPLUS

DOCUMENT NUMBER: 124:106623

TITLE: Antisense oligonucleotide to **papillomavirus**
 for diagnosis and **treatment** of infection

INVENTOR(S): Crooke, Stanley T.; Mirabelli, Christopher K.; Ecker,
 David J.; Cowser, Lex M.

PATENT ASSIGNEE(S): Isis Pharmaceuticals, USA

SOURCE: U.S., 39 pp. Cont.-in-part of U.S. Ser. No. 984,263.
 CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5457189	A	19951010	US 1992-860925	19920331
CA 2070664	AA	19910605	CA 1990-2070664	19901203
HU 62944	A2	19930628	HU 1992-1865	19901203
AT 163973	E	19980315	AT 1991-902031	19901203
WO 9320095	A1	19931014	WO 1993-US3075	19930331
W: AU, BB, BG, BR, CA, CZ, FI, HU, JP, KP, KR, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9339438	A1	19931108	AU 1993-39438	19930331
AU 671630	B2	19960905		
EP 637316	A1	19950208	EP 1993-908714	19930331
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 07501709	T2	19950223	JP 1993-517699	19930331
HU 69934	A2	19950928	HU 1994-2822	19930331
JP 09117291	A2	19970506	JP 1996-214477	19930331
NO 9403198	A	19940829	NO 1994-3198	19940829
FI 9404523	A	19940929	FI 1994-4523	19940929
US 5665580	A	19970909	US 1994-307682	19941014
US 5681944	A	19971028	US 1994-334215	19941104
US 5756282	A	19980526	US 1995-370517	19950109

PRIORITY APPLN. INFO.: US 1989-445196 A2 19891204
 US 1992-860925 A1 19920331
 JP 1993-517699 A3 19930331
 WO 1993-US3075 A 19930331

AB Oligonucleotides are provided which are capable of antisense interaction with mRNA of **papillomavirus**. Such oligonucleotides or oligonucleotide analogs can be used for diagnostics and **therapeutics** as well as for research purposes. In accordance with preferred embodiments of this invention, oligonucleotide ISIS 2105 is provided which hybridizes with selected mRNA from a human **papillomavirus**. The oligonucleotide is able to inhibit the function of the RNA, and accordingly is useful for **therapy** for infections by such **papillomavirus**. In accordance with a preferred embodiment, portions of the **papillomavirus** are targeted for antisense attack. Thus oligonucleotides are preferably provided which hybridize with the E2, E6 and E7 mRNAs.

L25 ANSWER 35 OF 39 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1995:559824 HCAPLUS
 DOCUMENT NUMBER: 123:47895
 TITLE: Peptide-nucleic acid oligomers for modulating cytomegaloviral and **papillomaviral** processes
 INVENTOR(S): Anderson, Kevin P.; Crooke, Stanley T.; Mirabelli, Christopher K.; Ecker, David J.; Cowsert, Lex M.
 PATENT ASSIGNEE(S): Isis Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 64 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9504748	A1	19950216	WO 1994-US9039	19940809
W:	AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN			
RW:	KE, MW, SD, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
AU 9475237	A1	19950228	AU 1994-75237	19940809
PRIORITY APPLN. INFO.:			US 1993-104438	19930809
			WO 1994-US9039	19940809

AB Oligomers are provided which are useful for modulating viral processes such as cytomegalovirus and **papillomaviruses**. The oligomers are comprised of subunits, at least one of which is a protein-nucleic acid (PNA) subunit. **Therapeutic** and diagnostic methods are also provided. Thus, 79 PNA oligomers were synthesized targeted to the translation initiation codon (AUG), coding sequence, 5'-cap, intron/exon (I/E) junction, or 5'- untranslated region (UTR) of cytomegalovirus genes selected from the group consisting of DNA polymerase, and nuclear localization signals of IE1 and IE2. Similarly, 35 PNA oligomers were targeted to the early and late open reading frames E1, E2, E4, E5, E6, E7, L1 and L2 of the **papillomavirus** genome. It is expected that **treatment** of cells with oligomers directed to cytomegalovirus will reduced the infectious yield of the same cells. The **papillomavirus** oligomers have against BPV-1 and HPV E2 expression, HPV E7 expression, BPV-1 E1 expression, exptl.-induced bovine fibropapillomas, E2-dependent transactivation, viral focus formation, and oral and cervical cancer (HPV-18) cells.

L25 ANSWER 36 OF 39 HCAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 1994:210049 HCAPLUS

DOCUMENT NUMBER: 120:210049
 TITLE: Ribozymes for prevention of replication of RNA viruses
 INVENTOR(S): Draper, Kenneth G.; Dudycz, Lech W.; Mcswiggen, James A.; Macejak, Dennis G.; Holeccek, James J.; Mamone, J. Anthony
 PATENT ASSIGNEE(S): Ribozyme Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 287 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 111
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9323569	A1	19931125	WO 1993-US4020	19930429
W: AU, CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5496698	A	19960305	US 1992-987130	19921207
AU 9342229	A1	19931213	AU 1993-42229	19930429
AU 687736	B2	19980305		
EP 642589	A1	19950315	EP 1993-910893	19930429
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 08500481	T2	19960123	JP 1993-520255	19930429
US 5646020	A	19970708	US 1993-166664	19931210
US 5622854	A	19970422	US 1994-192941	19940207
US 6258585	B1	20010710	US 1994-192946	19940207
US 5525468	A	19960611	US 1994-284746	19940801
US 5686599	A	19971111	US 1995-432876	19950502
US 6469158	B1	20021022	US 1995-433218	19950502
US 5631360	A	19970520	US 1995-435232	19950505
US 5804683	A	19980908	US 1995-435113	19950505
US 5795778	A	19980818	US 1996-623891	19960325
US 5972699	A	19991026	US 1997-835269	19970408
US 5977343	A	19991102	US 1997-911869	19970815
US 5831071	A	19981103	US 1997-919568	19970829
AU 9851819	A1	19980611	AU 1998-51819	19980112
AU 729657	B2	20010208		
US 6353098	B1	20020305	US 1998-99083	19980617
US 6432704	B1	20020813	US 1999-340861	19990628
AU 9939188	A1	19990916	AU 1999-39188	19990713
US 6437117	B1	20020820	US 1999-363238	19990727
US 6440719	B1	20020827	US 2000-634262	20000808
AU 769175	B2	20040115	AU 2000-56616	20000911
US 2003166917	A1	20030904	US 2002-156432	20020528
US 6649751	B2	20031118		
US 2003088087	A1	20030508	US 2002-231874	20020830
PRIORITY APPLN. INFO.:				
			US 1992-882689	A 19920511
			US 1992-882712	A 19920514
			US 1992-882713	A 19920514
			US 1992-882714	A 19920514
			US 1992-882823	A 19920514
			US 1992-882824	A 19920514
			US 1992-882886	A 19920514
			US 1992-882888	A 19920514
			US 1992-882889	A 19920514
			US 1992-882921	A 19920514
			US 1992-882922	A 19920514
			US 1992-883823	A 19920514

US 1992-883849	A	19920514
US 1992-884073	A	19920514
US 1992-884074	A	19920514
US 1992-884333	A	19920514
US 1992-884422	A	19920514
US 1992-884431	A	19920514
US 1992-884436	A	19920514
US 1992-884521	A	19920514
US 1992-923738		19920731
US 1992-935854		19920826
US 1992-936086		19920826
US 1992-948359		19920918
US 1992-963322		19921015
US 1992-987129		19921207
US 1992-987130		19921207
US 1992-987133		19921207
WO 1993-US4020		19930429
US 1993-167586	B2	19931214
US 1994-238200	B1	19940504
US 1994-245736	B2	19940518
US 1994-345516	B2	19941128
US 1995-380734	A3	19950130
US 1995-432876	A1	19950502
US 1995-433218	A1	19950502
US 1995-434559	B1	19950502
AU 1995-26422	A3	19950518
US 1996-623891	A1	19960325
AU 1996-76662	A3	19961025
US 1997-835269	A1	19970408
US 1997-911869	A1	19970815
US 1997-919568	A1	19970829
US 1999-340861	A1	19990628
US 1999-363238	A1	19990727

AB Ribozymes that specifically cleave a viral RNA (picornavirus, immunodeficiency virus) in a gene needed in viral replication, e.g., the vif, nef, tat or rev genes are described for **therapeutic** use (no data). The enzymes are also used to cleave RNA of a hepatitis virus, T-cell leukemia virus, hepatitis C virus, mRNA or rhRNA of a cytomegalovirus, and influenza virus RNA, and a herpes simplex virus mRNA mol. These enzymes are optimized to make them as small as possible and methods and reagents useful in selection and optimization of ribozymes are described. The ribozyme may be a hammerhead, a hairpin, hepatitis delta virus, group I intron or RNaseP-like RNA and is manufactured by expression of the cloned in a bacterial or animal cell host or by synthesis if the enzyme is short. Furthermore, defective viral particles shed by cells in which the ribozyme is active may act as antigens to improve immune response to the virus (no data). Suitable cleavage sites in appropriate genes are identified by sequence comparison and by modeling of the folded structure of the mRNA. Random and directed methods for optimizing the properties of a hammerhead enzyme are demonstrated.

L25 ANSWER 37 OF 39 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1993:230023 HCAPLUS

DOCUMENT NUMBER: 118:230023

TITLE: In vitro evaluation of phosphorothioate
oligonucleotides targeted to the E2 mRNA of
papillomavirus: potential treatment
for genital **warts**

AUTHOR(S): Cowsert, Lex M.; Fox, Maureen C.; Zon, Gerald;

CORPORATE SOURCE: Mirabelli, Christopher K.
 SOURCE: ISIS Pharm., Carlsbad, CA, 92008, USA
 Antimicrobial Agents and Chemotherapy (1993), 37(2),
 171-7

CODEN: AMACCO; ISSN: 0066-4804

DOCUMENT TYPE: Journal

LANGUAGE: English

AB **Papillomaviruses** induce benign proliferative lesions, such as genital warts, in humans. The E2 gene product is thought to play a major role in the regulation of viral transcription and DNA replication and may represent a rational target for an antisense oligonucleotide drug action. Phosphorothioate oligonucleotides complementary to E2 mRNAs were synthesized and tested in a series of in vitro bovine **papillomavirus** (BPV) and human **papillomavirus** (HPV) models for the ability to inhibit E2 transactivation and virus-induced focus formation. The most active BPV-specific compds. were complementary to the mRNA cap region (ISIS 1751), the translation initiation region for the full-length E2 transactivator (ISIS 1753), and the translation initiation region for the E2 transrepressor mRNA (ISIS 1755). ISIS 1751 and ISIS 1753 were found to reduce E2-dependent transactivation and viral focus formation in a sequence-specific and concentration-dependent manner.

ISIS

1755 increased E2 transactivation in a dose-dependent manner but had no effect on focus formation. Oligonucleotides with a chain length of 20 residues had optimal activity in the E2 transactivation assay. On the basis of the above observations, ISIS 2105, a 20-residue phosphorothioate oligonucleotide targeted to the translation initiation of both HPV type 6 (HPV-6) and HPV-11 E2 mRNA, was designed and shown to inhibit E2-dependent transactivation by HPV-11 E2 expressed from a surrogate promoter. These observations support the rationale of E2 as a target for antiviral **therapy** against **papillomavirus** infections and specifically identify ISIS 2105 as a candidate antisense oligonucleotide for the **treatment** of genital warts induced by HPV-6 and HPV-11.

L25 ANSWER 38 OF 39. HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1993:97582 HCAPLUS

DOCUMENT NUMBER: 118:97582

TITLE: Method of immobilizing and crosslinking proteins and other molecules and uses thereof

INVENTOR(S): Anderson, Leslie Deriemer; Cook, James Allen; David, Gary Samuel; Hochschwender, Susan Marie; Kasher, Mary Seybold; Smith, Michele Ceceil; Stemmer, William Peter Christian

PATENT ASSIGNEE(S): USA

SOURCE: Eur. Pat. Appl., 88 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 497585	A2	19920805	EP 1992-300775	19920130
EP 497585	A3	19930505		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, PT, SE				
CA 2060235	AA	19920731	CA 1992-2060235	19920129
AU 9210545	A1	19920806	AU 1992-10545	19920129

AU 652021 B2 19940811
 ZA 9200617 A 19930729 ZA 1992-617 19920129
 WO 9213965 A1 19920820 WO 1992-US679 19920130
 W: AU, BB, BG, BR, CA, CS, FI, HU, JP, KP, KR, LK, MG, MW, NO, PL,
 RO, RU, SD
 RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GN,
 GR, IT, LU, MC, ML, MR, NL, SE, SN, TD, TG
 AU 9213652 A1 19920907 AU 1992-13652 19920130
 JP 06157600 A2 19940603 JP 1992-15038 19920130

PRIORITY APPLN. INFO.: US 1991-647901 A 19910130
 WO 1992-US679 A 19920130

AB A method is disclosed for immobilizing and purifying proteins. Also provided is a method for the formation of a kinetically inert complex between a transition metal ion and a biol. active mol. or reporter group which possesses a metal binding site to form a kinetically inert complex between the CP-protein (CP = chelating peptide) and the bound metal ion. This kinetically inert (immobilized metal/CP-protein) complex provides a component of an assay system useful for studying the interaction of any of a variety of ligands with the immobilized CP-protein. Also provided is a method of purifying immunoreactive proteins (IPs; antibodies, antibody fragments, etc.) or receptors on a solid support. Immobilization of IPs or other biol. active mols. using the methodol. of the invention enables the orientation of the mols. so as to maximize exposure of the antigen or ligand binding site in an affinity chromatog. system. Further provided is a method of forming heterodimeric, homodimeric, or multimeric complexes by crosslinking ≥ 2 biol. active mols. or reporter groups with metal binding sites. Thus, plasmid p16E7e was constructed and expressed in Escherichia coli for the production of a fusion product containing the human **papillomavirus** 16 E7 oncoprotein sequence and a CP (Met-His-Trp-His-His-His) sequence. The protein was immobilized on a Co(II)-IDA-resin (IDA = iminodiacetic acid), and the resulting kinetically labile resin was converted to the corresponding kinetically inert resin by oxidation of the Co(II) to Co(III). The resin bound RB (anti-oncoprotein derived from human retinoblastoma gene) specifically, and the binding could be diminished by competition with excess free E7 or CP-E7. Preparation of an anti-carcinoembryonic antigen antibody construct containing a CP, and immobilization of the antibody onto a Ni-mica surface via the CP, are also described.

L25 ANSWER 39 OF 39 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1992:711 HCAPLUS

DOCUMENT NUMBER: 116:711

TITLE: Antisense oligonucleotide inhibition and detection of **papillomavirus**

INVENTOR(S): Crooke, Stanley T.; Mirabelli, Christopher K.; Ecker, David J.; Cowser, Lex M.

PATENT ASSIGNEE(S): Isis Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 63 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9108313	A1	19910613	WO 1990-US7067	19901203
W: AU, BR, CA, FI, HU, JP, KR, NO, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				

CA 2070664	AA	19910605	CA 1990-2070664	19901203
AU 9171756	A1	19910626	AU 1991-71756	19901203
AU 650257	B2	19940616		
EP 503002	A1	19920916	EP 1991-902031	19901203
EP 503002	B1	19980311		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE

BR 9007892	A	19920929	BR 1990-7892	19901203
JP 05501058	T2	19930304	JP 1991-502693	19901203
HU 62944	A2	19930628	HU 1992-1865	19901203
AT 163973	E	19980315	AT 1991-902031	19901203
NO 9202169	A	19920727	NO 1992-2169	19920601
FI 9202593	A	19920604	FI 1992-2593	19920604

PRIORITY APPLN. INFO.:

US 1989-445196 A2 19891204

WO 1990-US7067 A 19901203

AB Oligonucleotides and oligonucleotide analogs are provided which are capable of antisense interaction with mRNA of **papillomavirus** (PV). These oligonucleotides are useful for diagnostics and **therapeutics** as well as for research purposes. The oligonucleotides preferably hybridize with the E2, E1, E7 or E6-7 mRNAs. I-38 cells stably transformed by bovine PV-1 (BPV-1) were **treated** with I1753 and I1751 (oligonucleotides targeted to the translation codon for the E2 transactivator and the mRNA CAP region, resp.) and the viral DNA was quantitated. After 48 h of **treatment** at 1 μ M, the viral DNA copy number on a per cell basis was reduced by a factor of .apprx.3. During the course of this assay, the cells divided 2-3 times. Thus, the viral DNA failed to replicate synchronously with the cellular DNA. The 2 oligonucleotides had a 50% inhibitory concentration IC50 of 10 and 100 nm, resp. against BPV-1 transformation of C127 cells.